Latest Radiopharmacology Stories

LUBBOCK, Texas, Feb. 22, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is proud to announce that on February 15, 2012, MIT, in partnership with Los Alamos National Laboratory, was awarded the 2012 Federal Laboratory Consortium 'Excellence in Technology Transfer Award' for "Recycling of Strontium-82 for Use in Medical Diagnostic Imaging". The Award for Excellence in Technology Transfer is...

LUBBOCK, Texas, Feb. 21, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is proud to announce that on February 16, 2012, MIT, received its first shipment of strontium-82(Sr-82) from the ARRONAX Cyclotron Facility in Nantes, France. This historic event marks the first shipment of Sr-82 to be received by a private, non-government, entity in the U.S. in support of Sr-82 production. The receipt of...

FISHERS, Ind., Feb. 7, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is pleased to announce the execution of a Memorandum of Understanding with the Institute of Nuclear Research (INR) of Troitsk, Russia. MIT and INR will collaborate on strontium-82(Sr-82) production beginning with a pharmaceutical ingredient validation exercise in 2012. A key goal of the collaboration is to increase the annual...

Canadian centre of excellence partners with US-based Molecular Insight Pharmaceuticals to manufacture a new radiopharmaceutical for clinical trials that will evaluate the potential to deliver targeted radiotherapy directly to metastatic prostate cancer. HAMILTON, ON, and CAMBRIDGE, MA, Jan. 30, 2012 /PRNewswire/ - A new targeted radiopharmaceutical, designed to deliver a therapeutic dose of radiation directly to metastatic prostate cancer, will be manufactured in Hamilton,...

FISHERS, Ind., Jan. 27, 2012 /PRNewswire/ -- Positron Corporation (OTCBB:POSC), a leading molecular imaging healthcare company, specializing in the field of nuclear cardiology, is pleased to announce that on January 23, 2012, its wholly owned subsidiary, Manhattan Isotope Technology (MIT), received approval of its radioactive materials license amendment. The Texas Department of State Health Services- Radiation Control Program granted the amendment approval. This specific...

FISHERS, Ind., Jan. 17, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce the acquisition of Manhattan Isotope Technology, LLC (MIT). Positron has acquired all of the assets, business operations and retained all employees of MIT. In exchange, MIT shall receive cash advances, assumption of certain indebtedness and earn-out consideration of $3,500,000 based on 20...

FISHERS, Ind., Dec. 19, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce that on December 16, 2011, the Company received a nuclear pharmacy license from the Indiana Board of Pharmacy for the Company's Crown Point, Indiana manufacturing facility. The Indiana Board of Pharmacy license completes the requirements necessary to amend its NRC license to allow Positron to...

FISHERS, Ind., Dec. 2, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, is pleased to announce that Amerinet has awarded a Group Purchasing Agreement for their PosiRx system to begin January 1, 2012 for a three-year period. Amerinet is a Group Purchasing Organization (GPO), which enters into arrangements for the purchase of products and services on behalf of its member...

BERLIN, October 12, 2011 /PRNewswire/ -- OctreoPharm Sciences GmbH, a Berlin based specialist for radiopharmaceuticals, announced today that the European Medicines Agency has granted Orphan Drug status to OctreoPharm Sciences product SOMscan(R) for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours. The Orphan Drug status entitles OctreoPharm Sciences to ten year market exclusivity in Europe following marketing approval for SOMscan(R). The designation also...

BERLIN, October 6, 2011 /PRNewswire/ -- OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear medical pharmaceuticals (radiopharmaceuticals), announced today that it has received the worldwide exclusive license for the development and commercialization of SOMscan(TM), from Novartis Pharma AG. The new Gallium-68-labeled radioactive contrast agent for positron emission tomography (PET) used by SOMscan has the potential to selectively detect and monitor...